NextPlat (NXPL) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 08, 2023
Document Information [Line Items]
Entity Central Index Key	0001058307
Entity Registrant Name	NextPlat Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-40447
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	65-0783722
Entity Address, Address Line One	3250 Mary St., Suite 410
Entity Address, City or Town	Coconut Grove
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33133
City Area Code	305
Local Phone Number	560-5355
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,724,596
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	NXPLW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	NXPL
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 26,345,704	$ 18,891,232
Accounts receivable, net	7,802,121	383,786
Receivables - other, net	2,945,327	0
Inventory, net	4,986,734	1,286,612
Unbilled revenue	168,678	141,702
VAT receivable	369,422	432,769
Prepaid expenses	865,766	45,679
Notes receivable	251,485	0
Total Current Assets	43,735,237	21,181,780
Property and equipment, net	4,046,854	1,245,802
Goodwill	3,144,000	0
Intangible assets, net	14,116,748	50,001
Operating right of use assets, net	1,035,269	854,862
Finance right-of-use assets, net	28,807	0
Equity method investment	0	5,260,525
Deposits	39,137	0
Prepaid expenses, net of current portion	49,135	49,078
Total Other Assets	18,413,096	6,214,466
Total Assets	66,195,187	28,642,048
Current Liabilities
Accounts payable and accrued expenses	13,680,665	1,518,095
Contract liabilities	29,223	36,415
Notes payable	385,303	60,490
Due to related party	25,001	28,467
Operating lease liabilities	366,494	208,660
Finance lease liabilities	20,691	0
Income taxes payable	178,310	94,244
Liabilities from discontinued operations	0	112,397
Total Current Liabilities	14,685,687	2,058,768
Long Term Liabilities:
Long-term portion of notes payable	1,251,159	156,266
Operating lease liabilities, net of current portion	712,521	649,895
Finance lease liabilities, net of current portion	9,897	0
Total Liabilities	16,659,264	2,864,929
Commitments and Contingencies
Equity
Preferred stock ($0.0001 par value; 3,333,333 shares authorized)	0	0
Common stock ($0.0001 par value; 50,000,000 shares authorized, 18,724,596 and 14,402,025 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively)	1,872	1,440
Additional paid-in capital	66,469,956	56,963,200
Accumulated deficit	(33,227,122)	(31,146,804)
Accumulated other comprehensive loss	(56,869)	(40,717)
Equity attributable to NextPlat Corp stockholders	33,187,837	25,777,119
Equity attributable to noncontrolling interests	16,348,086	0
Total Equity	49,535,923	25,777,119
Total Liabilities and Equity	$ 66,195,187	$ 28,642,048

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	3,333,333	3,333,333
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,724,596	14,402,025
Common stock, shares outstanding (in shares)	18,724,596	14,402,025

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 15,290,171	$ 2,630,826	$ 21,123,687	$ 9,080,083
Cost of revenue	10,705,489	1,952,072	15,074,319	7,032,847
Gross profit	4,584,682	678,754	6,049,368	2,047,236
Operating expenses:
Selling, general and administrative	4,187,429	1,699,711	7,495,601	3,434,916
Salaries, wages and payroll taxes	2,483,432	651,219	4,039,307	1,957,592
Professional fees	520,726	356,306	1,385,474	839,509
Depreciation and amortization	871,066	136,457	1,200,825	348,022
Total operating expenses	8,062,653	2,843,693	14,121,207	6,580,039
Loss before other (income) expense	(3,477,971)	(2,164,939)	(8,071,839)	(4,532,803)
Other (income) expense:
Interest expense	45,949	8,725	55,657	15,649
Interest earned	(209,798)	(3,849)	(392,545)	(13,421)
Other income	0	0	(315,845)	0
Foreign currency exchange rate variance	164,504	89,025	95,831	229,753
Total other (income) expense	655	93,901	(556,902)	231,981
Loss before income taxes and equity in net loss of affiliate	(3,478,626)	(2,258,840)	(7,514,937)	(4,764,784)
Income taxes	(23,011)	0	(75,034)	0
Loss before equity in net loss of affiliate	(3,501,637)	(2,258,840)	(7,589,971)	(4,764,784)
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition	6,138,051	0	6,138,051	0
Equity in net loss of affiliate	0	(3,454,436)	(1,439,637)	(3,454,436)
Net income (loss)	2,636,414	(5,713,276)	(2,891,557)	(8,219,220)
Net loss attributable to noncontrolling interest	811,239	0	811,239	0
Net income (loss) attributable to NextPlat Corp	3,447,653	(5,713,276)	(2,080,318)	(8,219,220)
Comprehensive income (loss):
Net income (loss)	2,636,414	(5,713,276)	(2,891,557)	(8,219,220)
Foreign currency gain (loss)	18,801	(67,635)	(16,152)	(87,753)
Comprehensive income (loss)	2,655,215	(5,780,911)	(2,907,709)	(8,306,973)
Net loss	$ 3,447,653	$ (5,713,276)	$ (2,080,318)	$ (8,219,220)
Basic weighted average common shares outstanding (in shares)	18,702,857	9,469,509	17,079,077	9,310,936
Weighted number of common shares outstanding – diluted (in shares)	20,295,549	9,469,509	17,079,077	9,310,936
Basic weighted average earnings (loss) per common share (in dollars per share)	$ 0.18	$ (0.6)	$ (0.12)	$ (0.88)
Diluted weighted average earnings (loss) per common share (in dollars per share)	$ 0.17	$ (0.6)	$ (0.12)	$ (0.88)
Product [Member]
Revenue	$ 12,788,758	$ 2,630,826	$ 18,622,274	$ 9,080,083
Cost of revenue	10,633,953	1,952,072	15,002,783	7,032,847
Service [Member]
Revenue	2,501,413	0	2,501,413	0
Cost of revenue	$ 71,536	$ 0	$ 71,536	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021	7,053,146
Issuance of common stock related to restricted stock award (in shares)	10,000
Issuance of common stock related to restricted stock award	$ 1	$ 34,799	$ 0	$ 0			$ 34,800
Issuance of common stock related to April offering (in shares)	2,229,950
Issuance of common stock related to April offering	$ 223	7,004,815	0	0			7,005,038
Balance (in shares) at Mar. 31, 2022	9,293,096
Balance at Dec. 31, 2021	$ 705	39,513,093	(21,986,215)	3,236			17,530,819
Comprehensive loss	0	0	0	(15,330)			(15,330)
Net loss	0	0	(850,083)	0			(850,083)
Balance at Mar. 31, 2022	$ 929	46,552,707	(22,836,298)	(12,094)			23,705,244
Balance (in shares) at Dec. 31, 2021	7,053,146
Net loss							(8,219,220)
Balance (in shares) at Sep. 30, 2022	9,649,096
Balance at Dec. 31, 2021	$ 705	39,513,093	(21,986,215)	3,236			17,530,819
Net loss							(8,219,220)
Balance at Sep. 30, 2022	$ 965	48,481,636	(30,205,435)	(84,517)			18,192,649
Balance (in shares) at Mar. 31, 2022	9,293,096
Issuance of common stock related to restricted stock award	$ 0	654,246	0	0			654,246
Balance (in shares) at Jun. 30, 2022	9,293,096
Balance at Mar. 31, 2022	$ 929	46,552,707	(22,836,298)	(12,094)			23,705,244
Comprehensive loss	0	0	0	(4,788)			(4,788)
Net loss	0	0	(1,655,861)	0			(1,655,861)
Balance at Jun. 30, 2022	$ 929	47,206,953	(24,492,159)	(16,882)			22,698,841
Issuance of common stock related to restricted stock award (in shares)	356,000
Issuance of common stock related to restricted stock award	$ 36	654,484	0	0			654,520
Net loss							(5,713,276)
Stock-based compensation in connection with options granted	$ 0	620,199	0	0			620,199
Balance (in shares) at Sep. 30, 2022	9,649,096
Comprehensive loss	$ 0	0	0	(67,635)			(67,635)
Net loss	0	0	(5,713,276)	0			(5,713,276)
Balance at Sep. 30, 2022	$ 965	48,481,636	(30,205,435)	(84,517)			18,192,649
Balance (in shares) at Dec. 31, 2022	14,402,025
Balance at Dec. 31, 2022	$ 1,440	56,963,200	(31,146,804)	(40,717)	$ 25,777,119	$ 0	25,777,119
Issuance of common stock related to restricted stock award (in shares)	39,000
Issuance of common stock related to restricted stock award	$ 4	60,536	0	0	60,540	0
Comprehensive loss	0	0	0	(22,985)	(22,985)	0
Net loss	$ 0	0	(1,187,230)	0	(1,187,230)	0
Balance (in shares) at Mar. 31, 2023	14,441,025
Balance at Mar. 31, 2023	$ 1,444	57,023,736	(32,334,034)	(63,702)	24,627,444	0
Balance at Dec. 31, 2022							25,777,119
Balance (in shares) at Dec. 31, 2022	14,402,025
Balance at Dec. 31, 2022	$ 1,440	56,963,200	(31,146,804)	(40,717)	25,777,119	0	25,777,119
Net loss							(2,891,557)
Balance (in shares) at Sep. 30, 2023	18,724,596
Balance at Sep. 30, 2023	$ 1,872	66,469,956	(33,227,122)	(56,869)	33,187,837	16,348,086	49,535,923
Balance at Dec. 31, 2022							25,777,119
Net loss							(2,080,318)
Balance at Sep. 30, 2023							33,187,837
Balance (in shares) at Mar. 31, 2023	14,441,025
Balance at Mar. 31, 2023	$ 1,444	57,023,736	(32,334,034)	(63,702)	24,627,444	0
Issuance of common stock related to restricted stock award (in shares)	725,000
Issuance of common stock related to restricted stock award	$ 73	1,183,061	0	0	1,183,134	0
Comprehensive loss	0	0	0	(11,968)	(11,968)	0
Net loss	$ 0	0	(4,340,741)	0	(4,340,741)	0
Issuance of common stock related to April offering (in shares)	3,428,571
Issuance of common stock related to April offering	$ 343	5,999,657	0	0	6,000,000	0
Issuance of common stock related to exercise of warrants (in shares)	105,000
Issuance of common stock related to exercise of warrants	$ 10	183,740	0	0	183,750	0
Stock-based compensation in connection with options granted	$ 0	780,867	0	0	780,867	0
Balance (in shares) at Jun. 30, 2023	18,699,596
Balance at Jun. 30, 2023	$ 1,870	65,171,061	(36,674,775)	(75,670)	28,422,486	0
Issuance of common stock related to restricted stock award (in shares)	25,000
Issuance of common stock related to restricted stock award	$ 2	836,716	0	0	836,718	150,003
Comprehensive loss	0	0	0	18,801	18,801	0
Net loss	0	0	3,447,653	0	3,447,653	(811,239)	2,636,414
Stock-based compensation in connection with options granted	0	496,916	0	0	496,916
Acquisition of subsidiary and noncontrolling interests	$ 0	(34,737)		0	(34,737)	15,957,487
Acquisition of subsidiary and noncontrolling interests			0
Stock-based compensation in connection with options granted						1,051,835
Balance (in shares) at Sep. 30, 2023	18,724,596
Balance at Sep. 30, 2023	$ 1,872	$ 66,469,956	$ (33,227,122)	$ (56,869)	$ 33,187,837	$ 16,348,086	49,535,923
Net loss							3,447,653
Balance at Sep. 30, 2023							$ 33,187,837

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,891,557)	$ (8,219,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	539,235	329,272
Change in provision for doubtful accounts	12,000	0
Amortization of intangible assets	653,254	18,750
Amortization of right-of-use assets - operating leases	187,863	58,284
Amortization of right-of-use assets - finance leases	8,336	0
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition	(6,138,051)	0
Equity in net loss of affiliate	1,439,637	3,454,436
Stock-based compensation	4,560,013	1,343,566
Fair value of option granted	0	620,199
Change in operating assets and liabilities:
Accounts receivable	(3,897,500)	(339,258)
Inventory	(2,069,241)	(118,594)
Unbilled revenue	(26,976)	(19,937)
Prepaid expense	(342,831)	37,170
Notes receivable	(251,485)	0
Other assets	0	48,539
VAT receivable	63,347	136,299
Accounts payable and accrued expenses	4,120,297	23,700
Operating lease liabilities	(179,122)	(61,213)
Income taxes payable	84,066	(41,313)
Contract liabilities	(7,192)	(1,756)
Liabilities from discontinued operations	(112,397)	0
Net cash used in operating activities	(4,248,304)	(2,731,076)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(457,914)	(471,118)
Cash acquired in acquisition of subsidiary	7,352,183	0
Capital contributions to equity method investee	(1,506,000)	(7,000,000)
Net cash provided by (used in) investing activities	5,388,269	(7,471,118)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of note payable, related party, net	(3,467)	(19,616)
Issuance of common stock for PIPE transaction	6,000,000	5,605,038
Proceeds from exercise of warrants	689,750	0
Payments on finance lease liabilities	(7,962)	0
Repayments of notes payable	(347,830)	(51,104)
Net cash provided by financing activities	6,330,491	5,534,318
Effect of exchange rate on cash	(15,984)	(130,494)
Net increase (decrease) in cash	7,454,472	(4,798,370)
Cash beginning of period	18,891,232	17,267,978
Cash end of period	26,345,704	12,469,608
SUPPLEMENTAL CASH FLOW INFORMATION
Interest	353,566	10,137
Income tax	0	38,555
Supplemental schedule of non-cash investing and financing activities:
Recognition of operating lease liability	$ 0	$ 904,744

Note 1 - Organization & Nature

Note 1 - Organization & Nature of Operations.	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	1. The term “Company” refers to NextPlat Corp and its wholly, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Web3 Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not Progressive Care Inc.: Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Principles of Consolidation	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The accompanying Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2022 10 not 2022 10 not Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Certain 2022 2023 not Use of Estimates In preparing the Condensed Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 1 10 December 31, 2022 July 1, 2023 three September 30, 2023 Cash The Company places its cash with high credit quality financial institutions. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $2.1 million, are unsecured. In April 2023, $250,000. Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the nine September 30, 2023 nine September 30, 2022 December 31, 2022 Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At September 30, 2023 December 31, 2022 Accounts Receivable and Allowance for Doubtful Accounts Progressive Care trade accounts receivable are stated at the invoiced amount. Trade accounts receivable primarily include amounts from third no Goodwill Goodwill represents the excess of the purchase price of over the value assigned to net tangible and identifiable intangible assets. Progressive Care is considered to be the reporting unit for goodwill. Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. For intangible assets purchased in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the fourth may Direct and Indirect Remuneration ("DIR") Fees Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. For some pharmacy benefit managers ("PBMs"), DIR fees are charged at the time of the settlement of a pharmacy claim. Other PBMs do not two two three January – April 20xx July – August 20xx not may Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In June 2016, 2016 13, 326 2016 13” November 2018, 2018 19, 326, not April 2019, 2019 04, 326, 815, 825, 2016 13. March 2020, 2020 03, 842 326. 2016 13 December 15, 2022, January 1, 2023 no Other accounting standards that have been issued or proposed by FASB that do not not not not Subsequent Events The Company has evaluated subsequent events through November [ ], 2023,

Note 4 - Acquisition

Note 4 - Acquisition	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4. On July 1, 2023, Also, on July 1, 2023, As a result of the common stock purchase warrant exercises and the entry into the voting agreement, the Company concluded that there was a change in control in Progressive Care. As of July 1, 2023, 50 July 1, 2023, July 1, 2023 805. July 1, 2023. Final purchase accounting adjustments may may not 12 Progressive Care contributed revenues of approximately $12.4 million and a net loss of approximately $1.4 million to the Company for the period from July 1, 2023 September 30, 2023. January 1, 2022. For the Three Months Ended September 30, 2023 For the Three Months Ended September 30, 2022 (Unaudited) (Unaudited) Revenue $ 15,290,000 $ 12,775,000 Earnings $ 4,076,000 $ (13,777,000 ) For the Nine Months Ended September 30, 2023 For the Nine Months Ended September 30, 2022 (Unaudited) (Unaudited) Revenue $ 44,071,000 $ 39,248,000 Earnings $ (6,219,000 ) $ (16,511,000 ) The Company did not The following table summarizes the consideration transferred to acquire a controlling interest in Progressive Care and the amounts of identified assets acquired and liabilities assumed at the acquisition date, as well as the fair value of the noncontrolling interest in Progressive Care at the acquisition date: Purchase Price Allocation Total purchase consideration $ 11,465,000 Fair value of non-controlling interest 15,957,000 Total consideration $ 27,422,000 Identifiable net assets acquired - Provisional: Cash $ 7,352,000 Accounts receivable, net 6,478,000 Accounts receivable, other 506,000 Inventory 1,631,000 Prepaid expenses 220,000 Property and equipment, net 2,883,000 Right of use assets, net 405,000 Intangible assets, net: Trade name 4,060,000 Development technology 2,560,000 Pharmacy records 8,100,000 Other - Deposits 39,000 Accounts payable and accrued expenses (8,196,000 ) Notes payable and accrued interest - current portion (149,000 ) Lease liabilities - current portion (208,000 ) Notes payable - long term (1,173,000 ) Lease liabilities - long term (230,000 ) Net assets acquired $ 24,278,000 Goodwill $ 3,144,000 The total consideration is based on the fair value of Progressive Care’s common stock outstanding at July 1, 2023, As a result of NextPlat obtaining control over Progressive Care, NextPlat’s previously held equity interest in Progressive Care was remeasured to fair value, resulting in a gain of approximately $6.1 million, which has been recognized in the line item “Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition” on the condensed consolidated statements of comprehensive income (loss). The fair value of the noncontrolling interest of approximately $16.0 million and the fair value of the previously held equity interest of approximately $11.5 million in Progressive Care were estimated by applying a market approach and an income approach, respectively. These fair value measurements of the noncontrolling interest and the previously held equity interest are based on significant inputs not 3 1 2 3 4 The goodwill is attributable to the workforce of the acquired business and the significant synergies expected to arise after NextPlat’s acquisition of a controlling interest in Progressive Care. The goodwill is not

Note 5 - Fair Value

Note 5 - Fair Value	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 5. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Identifiable Intangible Assets The initial recognition of the Progressive Care's identifiable intangible assets, resulting from the acquisition on July 1, 2023 3

Note 6 - Revenue

Note 6 - Revenue	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 6. e-Commerce r The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third The Company accrues an estimate of pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories: Three Months Ended September 30, 2023 2022 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 9,887,890 $ - e-Commerce revenue 2,930,721 2,630,826 Sub total 12,818,611 2,630,826 Revenues from services: Pharmacy 340B contract revenue 2,471,560 - Revenues, net $ 15,290,171 $ 2,630,826 Nine Months Ended September 30, 2023 2022 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 9,887,890 $ - e-Commerce revenue 8,764,237 9,080,083 Sub total 18,652,127 9,080,083 Revenues from services: Pharmacy 340B contract revenue 2,471,560 - Revenues, net $ 21,123,687 $ 9,080,083

Note 7 - Earnings (Loss) Per Sh

Note 7 - Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 7. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net income (loss) attributable to NextPlat Corp common shareholders $ 3,447,653 $ (5,713,276 ) $ (2,080,318 ) $ (8,219,220 ) Basic weighted average common shares outstanding 18,702,857 9,469,509 17,079,077 9,310,936 Potentially dilutive common shares 1,592,692 - - - Diluted weighted average common shares outstanding 20,295,549 9,469,509 17,079,077 9,310,936 Basic weighted average earnings (loss) per common share $ 0.18 $ (0.60 ) $ (0.12 ) $ (0.88 ) Diluted weighted average earnings (loss) per common share $ 0.17 $ (0.60 ) $ (0.12 ) $ (0.88 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options - 273,607 156,327 292,959 Common stock purchase warrants - - 876,042 - - 273,607 1,032,369 292,959

Note 8 - Accounts Receivable

Note 8 - Accounts Receivable	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 10. On January 1, 2021, September 30, 2023 December 31, 2022 $369,000 $433,000
Accounts Receivable [Member]
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 8. At September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 (Unaudited) (Audited) Gross accounts receivable – trade $ 8,039,121 $ 383,786 Less: allowance for doubtful accounts (237,000 ) - Accounts receivable – trade, net $ 7,802,121 $ 383,786 Bad debt expense was approximately $12,000 and $ - three nine September 30, 2023 2022, Accounts receivable – trade, net for the Company as of January 1, 2022 September 30, 2022

Note 9 - Inventory

Note 9 - Inventory	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 9. At September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 (Unaudited) (Audited) Finished goods $ 5,026,734 $ 1,286,612 Less reserve for obsolete inventory (40,000 ) - Total $ 4,986,734 $ 1,286,612 The increase in inventory was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 10 - VAT Receivable

Note 10 - VAT Receivable	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 10. On January 1, 2021, September 30, 2023 December 31, 2022 $369,000 $433,000

Note 11 - Prepaid Expenses

Note 11 - Prepaid Expenses	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Prepaid Expenses [Text Block]	Note 11. Prepaid expenses current and long term amounted to approximately $866,000 $49,000 September 30, 2023 $46,000 $49,000 December 31, 2022 The increase in prepaid expenses was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 12 - Property and Equipmen

Note 12 - Property and Equipment, Net	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 12. Property and equipment, net consisted of the following: September 30, 2023 December 31, 2022 (Unaudited) (Audited) Building $ 2,116,000 $ - Vehicles 491,466 - Office furniture and fixtures 502,099 128,252 Land 184,000 - Leasehold improvements 123,630 47,792 Computer equipment 77,590 72,345 Rental equipment 57,759 37,531 Appliques 2,160,096 2,160,096 Website development 738,784 665,030 Property and equipment gross 6,451,424 3,111,046 Less: accumulated depreciation (2,404,570 ) (1,865,244 ) Property and equipment, net $ 4,046,854 $ 1,245,802 Depreciation expense was approximately $540,000 $329,000 nine September 30, 2023 2022 The increase in property and equipment was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 13 - Intangible Assets, Ne

Note 13 - Intangible Assets, Net	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 13. Intangible assets, net consisted of the following: September 30, 2023 December 31, 2022 (Unaudited) (Audited) Pharmacy records $ 8,100,000 $ - Trade names 4,060,000 - Developed technology 2,560,000 - Customer Contracts 250,000 250,000 Subtotal $ 14,970,000 $ 250,000 Less: accumulated amortization (853,252 ) (199,999 ) Net intangible assets $ 14,116,748 $ 50,001 Amortization of customer contracts is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss). For the nine September 30, 2023 2022 Year Amount 2023 (remaining three months) $ 640,748 2024 2,563,000 2025 2,538,000 2026 2,538,000 2027 2,538,000 Thereafter 3,299,000 Total $ 14,116,748 The increase in intangible assets was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 14 - Equity Method Investm

Note 14 - Equity Method Investment	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 14. On August 30, 2022, one one may In addition, on August 30, 2022, third On September 13, 2022, September 12, 2022, two October 7, 2022, On November 11, 2022, On December 29, 2022, one On May 5, 2023, one one three May 9, 2023, Simultaneous with the closing, Progressive Care entered into a Debt Conversion Agreement (the “DCA”) with NextPlat and the other holders (the “Holders”) of that certain Amended and Restated Secured Convertible Promissory Note, dated as of September 2, 2022, one three At the same time, Progressive Care and NextPlat entered into a First Amendment (the “Amendment”) to that certain Securities Purchase Agreement dated November 16, 2022 ( three As a result of the common stock purchase warrant exercises and the entry into the voting agreement as described in Note 4, July 1, 2023, 50 July 1, 2023, July 1, 2023 805. July 1, 2023. The following summarizes the Company’s consolidated balance sheet description equity method investment as follows as of September 30, 2023: Carrying Amount December 31, 2022, beginning balance $ 5,260,525 Investment in Progressive Care Inc. and Subsidiaries 1,506,000 Gain on equity method investment 6,138,051 Portion of loss from Progressive Care, Inc. and Subsidiaries (1,603,649 ) Depreciation expense due to cost basis difference (1) (49,548 ) Interest earned from convertible note receivable 21,443 Interest earned from amortization of premium on convertible note receivable 199,061 Elimination of intercompany interest earned (6,944 ) Change in accounting method as of July 1, 2023 (11,464,939 ) September 30, 2023, carrying amount $ - The following summarizes the Company’s consolidated statements of operations and comprehensive loss description equity in net loss of affiliate for the six June 30, 2023 For the six months ended June 30, 2023 Portion of loss from Progressive Care, Inc. and Subsidiaries $ (1,603,649 ) Depreciation expense due to cost basis difference (1) (49,548 ) Interest earned from convertible note receivable 21,443 Interest earned from amortization of premium on convertible note receivable 199,061 Elimination of intercompany interest earned (6,944 ) Equity in net loss of affiliate $ (1,439,637 ) (1) NextPlat records depreciation expense on its estimated cost basis difference which is subject to change

Note 15 - Accounts Payable and

Note 15 - Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 15. Accounts payable and accrued expenses consisted of the following: September 30, 2023 December 31, 2022 (Unaudited) (Audited) Accounts payable $ 12,362,513 $ 1,194,067 Accrued wages and payroll liabilities 366,569 23,040 Accrued PBM fees 650,000 - Rental deposits - 4,325 Customer deposits payable 55,748 86,462 VAT liability & sales tax payable 6,480 5,685 U.K. income tax payable - 23,771 Accrued legal fees - 84,685 Pre-merger accrued other liabilities - 88,448 Accrued interest 265 356 Accrued other liabilities 239,090 7,256 Total $ 13,680,665 $ 1,518,095 The increase in accounts payable and accrued expenses was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 16 - Notes Payable

Note 16 - Notes Payable	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 16. Notes payable consisted of the following: September 30, 2023 December 31, 2022 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,162,004 $ - B. Note payable - uncollateralized 25,000 - C. Notes payable - collateralized 270,906 216,756 Insurance premiums financing 178,552 - Subtotal 1,636,462 216,756 Less: current portion of notes payable (385,303 ) (60,490 ) Long-term portion of notes payable $ 1,251,159 $ 156,266 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of September 30, 2023 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 In April 2021, September 2021, September 30, 2023 In July 2022, January 2023. September 30, 2023. In September 2022, October 2022. September 30, 2023. Principal outstanding as of September 30, 2023, Year Amount 2023 (remaining three months) $ 144,420 2024 285,356 2025 175,435 2026 154,222 2027 123,597 Thereafter 753,432 Total $ 1,636,462 The increase in notes payables was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 17 - Stockholders' Equity

Note 17 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity [Text Block]	Note 17. Equity Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No preferred stock was outstanding for any year presented. As of September 30, 2023 Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of September 30, 2023 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not For the nine September 30, 2023 2022 nine September 30, 2023 2022

Note 18 - Related Party Transac

Note 18 - Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 18. On February 1, 2023, May 2023 nine September 30, 2023 On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, On August 30, 2022, March 6, 2019, On May 5, 2023, one one On May 9, 2023, one On July 1, 2023,

Note 19 - Commitments and Conti

Note 19 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 19. Litigation On June 22, 2021, not June 2021. not not not From time to time, the Company may not no On June 8, 2022,

Note 20 - Leases

Note 20 - Leases	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Lessee, Finance Leases and Operating Leases [Text Block]	Note 20. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 In December 2020, November 2023. Operating Lease Agreements On December 2, 2021, June 13, 2022, August 31, 2027. For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve The Florida lease does not not The rate implicit to the Florida lease is not six September 30, 2023 December 31, 2022 360 10, September 30, 2023 December 31, 2022 not We monitor for events or changes in circumstances that require a reassessment of one Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2024. The increase in leases was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 21 - Reportable Segments

Note 21 - Reportable Segments	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 21. The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two Three Months Ended September 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 9,887,890 $ - $ 9,887,890 e-Commerce revenue 2,930,721 - - 2,930,721 Pharmacy 340B contract revenue - 2,471,560 - 2,471,560 Revenues, net $ 2,930,721 $ 12,359,450 $ - $ 15,290,171 Expenses: Cost of revenue 2,126,602 8,578,887 - 10,705,489 Selling, general and administrative 1,978,743 2,268,708 (60,022 ) 4,187,429 Salaries, wages and payroll taxes 563,915 1,919,517 - 2,483,432 Professional fees 277,872 242,854 - 520,726 Depreciation and amortization 163,512 707,554 - 871,066 5,110,644 13,717,520 (60,022 ) 18,768,142 Loss before other (income) expense $ (2,179,923 ) $ (1,358,070 ) $ 60,022 $ (3,477,971 ) For the Nine Months Ended September 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 9,887,890 $ - $ 9,887,890 e-Commerce revenue 8,764,237 - - 8,764,237 Pharmacy 340B contract revenue - 2,471,560 - 2,471,560 Revenues, net $ 8,764,237 $ 12,359,450 $ - $ 21,123,687 Expenses: Cost of revenue 6,495,432 8,578,887 - 15,074,319 Selling, general and administrative 5,286,915 2,268,708 (60,022 ) 7,495,601 Salaries, wages and payroll taxes 2,119,790 1,919,517 - 4,039,307 Professional fees 1,142,620 242,854 - 1,385,474 Depreciation and amortization 493,271 707,554 - 1,200,825 15,538,028 13,717,520 (60,022 ) 29,195,526 Loss before other (income) expense $ (6,773,791 ) $ (1,358,070 ) $ 60,022 $ (8,071,839 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of September 30, 2023 $ 36,395,131 $ 41,264,995 $ (11,464,939 ) $ 66,195,187

Note 22 - Concentrations

Note 22 - Concentrations	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 22. e-Commerce operations concentrations: Customers: Sales to customers through Amazon accounted for 53.0% and 59.2% of the Company’s revenues during the nine September 30, 2023 2022 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% three September 30, 2023 2022 For the Three Months Ended September 30, 2023 For the Three Months Ended September 30, 2022 Globalstar Europe $ 186,000 9.7 % $ 109,000 6.7 % Garmin $ 444,000 23.2 % $ 281,000 17.1 % Network Innovations $ 188,000 9.9 % $ 252,000 15.4 % Satcom Global $ 226,000 11.8 % $ 131,000 8.0 % Cygnus Telecom $ 113,000 5.9 % $ 181,000 11.0 % The following table sets forth information as to each supplier that accounted for 10% nine September 30, 2023 2022 For the Nine Months Ended September 30, 2023 For the Nine Months Ended September 30, 2022 Iridium Satellite $ 798,000 12.0 % $ - - % Globalstar Europe $ 706,000 10.6 % $ 396,000 6.5 % Garmin $ 1,494,000 22.5 % $ 1,169,000 19.2 % Network Innovations $ 809,000 12.2 % $ 719,000 11.8 % Cygnus Telecom $ 476,000 7.2 % $ 1,213,000 19.9 % Geographic The following table sets forth revenue as to each geographic location, for the three September 30, 2023 2022 For the Three Months Ended September 30, 2023 For the Three Months Ended September 30, 2022 Europe $ 1,714,983 58.5 % $ 1,954,967 74.3 % North America 737,189 25.2 % 442,678 16.8 % South America 431,612 14.7 % 10,273 0.4 % Asia and Pacific 23,943 0.8 % 195,307 7.4 % Africa 22,994 0.8 % 27,601 1.1 % $ 2,930,721 100.0 % $ 2,630,826 100.0 % The following table sets forth revenue as to each geographic location, for the nine September 30, 2023 2022 For the Nine Months Ended September 30, 2023 For the Nine Months Ended September 30, 2022 Europe $ 5,381,938 61.4 % $ 7,019,811 77.3 % North America 2,194,309 25.0 % 1,342,636 14.8 % South America 1,025,566 11.7 % 32,578 0.4 % Asia and Pacific 120,836 1.4 % 592,847 6.5 % Africa 41,588 0.5 % 92,211 1.0 % $ 8,764,237 100.0 % $ 9,080,083 100.0 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 99% of total vendor purchases for the three September 30, 2023. Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care generated reimbursements from three Three Months Ended September 30, 2023 A 35 % B 31 % C 16 %

Note 23 - Subsequent Events

Note 23 - Subsequent Events	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 23. October 12, 2023, one one ninety

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company places its cash with high credit quality financial institutions. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $2.1 million, are unsecured. In April 2023, $250,000.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the nine September 30, 2023 nine September 30, 2022 December 31, 2022
Revenue from Contract with Customer [Policy Text Block]	Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At September 30, 2023 December 31, 2022
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Progressive Care trade accounts receivable are stated at the invoiced amount. Trade accounts receivable primarily include amounts from third no
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill represents the excess of the purchase price of over the value assigned to net tangible and identifiable intangible assets. Progressive Care is considered to be the reporting unit for goodwill. Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. For intangible assets purchased in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the fourth may
Direct and Indirect Remuneration Fees [Policy Text Block]	Direct and Indirect Remuneration ("DIR") Fees Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. For some pharmacy benefit managers ("PBMs"), DIR fees are charged at the time of the settlement of a pharmacy claim. Other PBMs do not two two three January – April 20xx July – August 20xx not may
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In June 2016, 2016 13, 326 2016 13” November 2018, 2018 19, 326, not April 2019, 2019 04, 326, 815, 825, 2016 13. March 2020, 2020 03, 842 326. 2016 13 December 15, 2022, January 1, 2023 no Other accounting standards that have been issued or proposed by FASB that do not not not not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company has evaluated subsequent events through November [ ], 2023,

Note 4 - Acquisition (Tables)

Note 4 - Acquisition (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]	For the Three Months Ended September 30, 2023 For the Three Months Ended September 30, 2022 (Unaudited) (Unaudited) Revenue $ 15,290,000 $ 12,775,000 Earnings $ 4,076,000 $ (13,777,000 ) For the Nine Months Ended September 30, 2023 For the Nine Months Ended September 30, 2022 (Unaudited) (Unaudited) Revenue $ 44,071,000 $ 39,248,000 Earnings $ (6,219,000 ) $ (16,511,000 )
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Purchase Price Allocation Total purchase consideration $ 11,465,000 Fair value of non-controlling interest 15,957,000 Total consideration $ 27,422,000 Identifiable net assets acquired - Provisional: Cash $ 7,352,000 Accounts receivable, net 6,478,000 Accounts receivable, other 506,000 Inventory 1,631,000 Prepaid expenses 220,000 Property and equipment, net 2,883,000 Right of use assets, net 405,000 Intangible assets, net: Trade name 4,060,000 Development technology 2,560,000 Pharmacy records 8,100,000 Other - Deposits 39,000 Accounts payable and accrued expenses (8,196,000 ) Notes payable and accrued interest - current portion (149,000 ) Lease liabilities - current portion (208,000 ) Notes payable - long term (1,173,000 ) Lease liabilities - long term (230,000 ) Net assets acquired $ 24,278,000 Goodwill $ 3,144,000

Note 6 - Revenue (Tables)

Note 6 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2023 2022 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 9,887,890 $ - e-Commerce revenue 2,930,721 2,630,826 Sub total 12,818,611 2,630,826 Revenues from services: Pharmacy 340B contract revenue 2,471,560 - Revenues, net $ 15,290,171 $ 2,630,826 Nine Months Ended September 30, 2023 2022 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 9,887,890 $ - e-Commerce revenue 8,764,237 9,080,083 Sub total 18,652,127 9,080,083 Revenues from services: Pharmacy 340B contract revenue 2,471,560 - Revenues, net $ 21,123,687 $ 9,080,083

Note 7 - Earnings (Loss) Per _2

Note 7 - Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net income (loss) attributable to NextPlat Corp common shareholders $ 3,447,653 $ (5,713,276 ) $ (2,080,318 ) $ (8,219,220 ) Basic weighted average common shares outstanding 18,702,857 9,469,509 17,079,077 9,310,936 Potentially dilutive common shares 1,592,692 - - - Diluted weighted average common shares outstanding 20,295,549 9,469,509 17,079,077 9,310,936 Basic weighted average earnings (loss) per common share $ 0.18 $ (0.60 ) $ (0.12 ) $ (0.88 ) Diluted weighted average earnings (loss) per common share $ 0.17 $ (0.60 ) $ (0.12 ) $ (0.88 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options - 273,607 156,327 292,959 Common stock purchase warrants - - 876,042 - - 273,607 1,032,369 292,959

Note 8 - Accounts Receivable (T

Note 8 - Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	September 30, 2023 December 31, 2022 (Unaudited) (Audited) Gross accounts receivable – trade $ 8,039,121 $ 383,786 Less: allowance for doubtful accounts (237,000 ) - Accounts receivable – trade, net $ 7,802,121 $ 383,786

Note 9 - Inventory (Tables)

Note 9 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2023 December 31, 2022 (Unaudited) (Audited) Finished goods $ 5,026,734 $ 1,286,612 Less reserve for obsolete inventory (40,000 ) - Total $ 4,986,734 $ 1,286,612

Note 12 - Property and Equipm_2

Note 12 - Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2023 December 31, 2022 (Unaudited) (Audited) Building $ 2,116,000 $ - Vehicles 491,466 - Office furniture and fixtures 502,099 128,252 Land 184,000 - Leasehold improvements 123,630 47,792 Computer equipment 77,590 72,345 Rental equipment 57,759 37,531 Appliques 2,160,096 2,160,096 Website development 738,784 665,030 Property and equipment gross 6,451,424 3,111,046 Less: accumulated depreciation (2,404,570 ) (1,865,244 ) Property and equipment, net $ 4,046,854 $ 1,245,802

Note 13 - Intangible Assets, _2

Note 13 - Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2023 December 31, 2022 (Unaudited) (Audited) Pharmacy records $ 8,100,000 $ - Trade names 4,060,000 - Developed technology 2,560,000 - Customer Contracts 250,000 250,000 Subtotal $ 14,970,000 $ 250,000 Less: accumulated amortization (853,252 ) (199,999 ) Net intangible assets $ 14,116,748 $ 50,001
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Amount 2023 (remaining three months) $ 640,748 2024 2,563,000 2025 2,538,000 2026 2,538,000 2027 2,538,000 Thereafter 3,299,000 Total $ 14,116,748

Note 14 - Equity Method Inves_2

Note 14 - Equity Method Investment (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Equity Method Investments [Table Text Block]	Carrying Amount December 31, 2022, beginning balance $ 5,260,525 Investment in Progressive Care Inc. and Subsidiaries 1,506,000 Gain on equity method investment 6,138,051 Portion of loss from Progressive Care, Inc. and Subsidiaries (1,603,649 ) Depreciation expense due to cost basis difference (1) (49,548 ) Interest earned from convertible note receivable 21,443 Interest earned from amortization of premium on convertible note receivable 199,061 Elimination of intercompany interest earned (6,944 ) Change in accounting method as of July 1, 2023 (11,464,939 ) September 30, 2023, carrying amount $ - For the six months ended June 30, 2023 Portion of loss from Progressive Care, Inc. and Subsidiaries $ (1,603,649 ) Depreciation expense due to cost basis difference (1) (49,548 ) Interest earned from convertible note receivable 21,443 Interest earned from amortization of premium on convertible note receivable 199,061 Elimination of intercompany interest earned (6,944 ) Equity in net loss of affiliate $ (1,439,637 ) (1) NextPlat records depreciation expense on its estimated cost basis difference which is subject to change

Note 15 - Accounts Payable an_2

Note 15 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, 2023 December 31, 2022 (Unaudited) (Audited) Accounts payable $ 12,362,513 $ 1,194,067 Accrued wages and payroll liabilities 366,569 23,040 Accrued PBM fees 650,000 - Rental deposits - 4,325 Customer deposits payable 55,748 86,462 VAT liability & sales tax payable 6,480 5,685 U.K. income tax payable - 23,771 Accrued legal fees - 84,685 Pre-merger accrued other liabilities - 88,448 Accrued interest 265 356 Accrued other liabilities 239,090 7,256 Total $ 13,680,665 $ 1,518,095

Note 16 - Notes Payable (Tables

Note 16 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2023 December 31, 2022 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,162,004 $ - B. Note payable - uncollateralized 25,000 - C. Notes payable - collateralized 270,906 216,756 Insurance premiums financing 178,552 - Subtotal 1,636,462 216,756 Less: current portion of notes payable (385,303 ) (60,490 ) Long-term portion of notes payable $ 1,251,159 $ 156,266
Schedule of Maturities of Long-Term Debt [Table Text Block]	Year Amount 2023 (remaining three months) $ 144,420 2024 285,356 2025 175,435 2026 154,222 2027 123,597 Thereafter 753,432 Total $ 1,636,462

Note 21 - Reportable Segments (

Note 21 - Reportable Segments (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Three Months Ended September 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 9,887,890 $ - $ 9,887,890 e-Commerce revenue 2,930,721 - - 2,930,721 Pharmacy 340B contract revenue - 2,471,560 - 2,471,560 Revenues, net $ 2,930,721 $ 12,359,450 $ - $ 15,290,171 Expenses: Cost of revenue 2,126,602 8,578,887 - 10,705,489 Selling, general and administrative 1,978,743 2,268,708 (60,022 ) 4,187,429 Salaries, wages and payroll taxes 563,915 1,919,517 - 2,483,432 Professional fees 277,872 242,854 - 520,726 Depreciation and amortization 163,512 707,554 - 871,066 5,110,644 13,717,520 (60,022 ) 18,768,142 Loss before other (income) expense $ (2,179,923 ) $ (1,358,070 ) $ 60,022 $ (3,477,971 ) For the Nine Months Ended September 30, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ - $ 9,887,890 $ - $ 9,887,890 e-Commerce revenue 8,764,237 - - 8,764,237 Pharmacy 340B contract revenue - 2,471,560 - 2,471,560 Revenues, net $ 8,764,237 $ 12,359,450 $ - $ 21,123,687 Expenses: Cost of revenue 6,495,432 8,578,887 - 15,074,319 Selling, general and administrative 5,286,915 2,268,708 (60,022 ) 7,495,601 Salaries, wages and payroll taxes 2,119,790 1,919,517 - 4,039,307 Professional fees 1,142,620 242,854 - 1,385,474 Depreciation and amortization 493,271 707,554 - 1,200,825 15,538,028 13,717,520 (60,022 ) 29,195,526 Loss before other (income) expense $ (6,773,791 ) $ (1,358,070 ) $ 60,022 $ (8,071,839 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of September 30, 2023 $ 36,395,131 $ 41,264,995 $ (11,464,939 ) $ 66,195,187

Note 22 - Concentrations (Table

Note 22 - Concentrations (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the Three Months Ended September 30, 2023 For the Three Months Ended September 30, 2022 Globalstar Europe $ 186,000 9.7 % $ 109,000 6.7 % Garmin $ 444,000 23.2 % $ 281,000 17.1 % Network Innovations $ 188,000 9.9 % $ 252,000 15.4 % Satcom Global $ 226,000 11.8 % $ 131,000 8.0 % Cygnus Telecom $ 113,000 5.9 % $ 181,000 11.0 % For the Nine Months Ended September 30, 2023 For the Nine Months Ended September 30, 2022 Iridium Satellite $ 798,000 12.0 % $ - - % Globalstar Europe $ 706,000 10.6 % $ 396,000 6.5 % Garmin $ 1,494,000 22.5 % $ 1,169,000 19.2 % Network Innovations $ 809,000 12.2 % $ 719,000 11.8 % Cygnus Telecom $ 476,000 7.2 % $ 1,213,000 19.9 % For the Three Months Ended September 30, 2023 For the Three Months Ended September 30, 2022 Europe $ 1,714,983 58.5 % $ 1,954,967 74.3 % North America 737,189 25.2 % 442,678 16.8 % South America 431,612 14.7 % 10,273 0.4 % Asia and Pacific 23,943 0.8 % 195,307 7.4 % Africa 22,994 0.8 % 27,601 1.1 % $ 2,930,721 100.0 % $ 2,630,826 100.0 % For the Nine Months Ended September 30, 2023 For the Nine Months Ended September 30, 2022 Europe $ 5,381,938 61.4 % $ 7,019,811 77.3 % North America 2,194,309 25.0 % 1,342,636 14.8 % South America 1,025,566 11.7 % 32,578 0.4 % Asia and Pacific 120,836 1.4 % 592,847 6.5 % Africa 41,588 0.5 % 92,211 1.0 % $ 8,764,237 100.0 % $ 9,080,083 100.0 % Three Months Ended September 30, 2023 A 35 % B 31 % C 16 %

Note 1 - Organization & Natur_2

Note 1 - Organization & Nature of Operations. (Details Textual)	Sep. 30, 2023
Progressive Care [Member] | Pharmco 901 [Member]
Subsidiary, Ownership Percentage, Parent	100%

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Principles of Consolidation (Details Textual)	Jul. 01, 2023
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired	53%

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022
Cash, FDIC Insured Amount	$ 250,000
Cash, Uninsured Amount	2,100,000
Contract with Customer, Liability	$ 29,000	$ 36,000
United Kingdom, Pounds | Closing Rate [Member]
Foreign Currency Exchange Rate, Translation	1.22	1.21	1.12
United Kingdom, Pounds | Quarterly Average Rate [Member]
Foreign Currency Exchange Rate, Translation	1.26	1.24	1.18
Maximum [Member]
Cash, FDIC Insured Amount	$ 250,000

Note 4 - Acquisition (Details T

Note 4 - Acquisition (Details Textual)		3 Months Ended		9 Months Ended
	Jul. 01, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	May 05, 2023 shares	Dec. 31, 2022 shares	Aug. 30, 2022 shares
Proceeds from Warrant Exercises				$ 689,750	$ 0
Common Stock, Shares, Outstanding (in shares) | shares		18,724,596		18,724,596				14,402,025
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain		$ 6,138,051	$ 0	$ 6,138,051	$ 0
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired	53%
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		12,400,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (1,400,000)
Common Stock, Shares, Outstanding (in shares) | shares	6,162,343
Share Price (in dollars per share) | $ / shares	$ 4.45
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain	$ 6,100,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	$ 15,957,000
Progressive Care [Member] | Measurement Input, Discount Rate [Member] | Minimum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input	0.10
Progressive Care [Member] | Measurement Input, Discount Rate [Member] | Maximum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input	0.11
Progressive Care [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member] | Minimum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input	0.03
Progressive Care [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member] | Maximum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input	0.048
Progressive Care [Member]
Investment Owned, Balance, Shares (in shares) | shares	402,269						455,000		3,000
Proceeds from Warrant Exercises	$ 506,000
Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares	230,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain				$ 6,138,051
Equity Method Investments, Fair Value Disclosure						$ 11,500,000
Progressive Care [Member] | Measurement Input, Discount Rate [Member] | Minimum [Member]
Equity Method Investment, Measurement Input						0.10
Progressive Care [Member] | Measurement Input, Discount Rate [Member] | Maximum [Member]
Equity Method Investment, Measurement Input						0.11
Progressive Care [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member] | Minimum [Member]
Equity Method Investment, Measurement Input						0.03
Progressive Care [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member] | Maximum [Member]
Equity Method Investment, Measurement Input						0.048
Progressive Care [Member] | Chief Executive Officer [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares	211,470
Progressive Care [Member] | Board Member [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares	130,571

Note 4 - Acquisition - Pro Form

Note 4 - Acquisition - Pro Forma Summary (Details) - Progressive Care [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 15,290,000	$ 12,775,000	$ 44,071,000	$ 39,248,000
Earnings	$ 4,076,000	$ (13,777,000)	$ (6,219,000)	$ (16,511,000)

Note 4 - Acquisition - Summary

Note 4 - Acquisition - Summary of Consideration Transferred in Business Acquisition (Details) - USD ($)	Jul. 01, 2023	Sep. 30, 2023	Dec. 31, 2022
Goodwill		$ 3,144,000	$ 0
Progressive Care [Member]
Total purchase consideration	$ 11,465,000
Fair value of non-controlling interest	15,957,000
Total consideration	27,422,000
Cash	7,352,000
Accounts receivable, net	6,478,000
Accounts receivable, other	506,000
Inventory	1,631,000
Prepaid expenses	220,000
Property and equipment, net	2,883,000
Right of use assets, net	405,000
Other	0
Deposits	39,000
Accounts payable and accrued expenses	(8,196,000)
Notes payable and accrued interest - current portion	(149,000)
Lease liabilities - current portion	(208,000)
Notes payable - long term	(1,173,000)
Lease liabilities - long term	(230,000)
Net assets acquired	24,278,000
Goodwill	3,144,000
Progressive Care [Member] | Trade Names [Member]
Finite-Lived Intangibles	4,060,000
Progressive Care [Member] | Developed Technology Rights [Member]
Finite-Lived Intangibles	2,560,000
Progressive Care [Member] | Pharmacy Records [Member]
Finite-Lived Intangibles	$ 8,100,000

Note 5 - Fair Value (Details Te

Note 5 - Fair Value (Details Textual) $ in Millions	Jul. 01, 2023 USD ($)
Progressive Care [Member] | Fair Value, Inputs, Level 3 [Member]
Finite-Lived Intangible Assets, Fair Value Disclosure	$ 14.7

Note 6 - Revenue - Disaggregati

Note 6 - Revenue - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 15,290,171	$ 2,630,826	$ 21,123,687	$ 9,080,083
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	9,887,890	0	9,887,890	0
E-Commerce [Member]
Revenue	2,930,721	2,630,826	8,764,237	9,080,083
Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue	12,818,611	2,630,826	18,652,127	9,080,083
Pharmacy 340B Contract [Member]
Revenue	$ 2,471,560	$ 0	$ 2,471,560	$ 0

Note 7 - Earnings (Loss) Per _3

Note 7 - Earnings (Loss) Per Share - Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net income (loss) attributable to NextPlat Corp common shareholders	$ 3,447,653	$ (5,713,276)	$ (2,080,318)	$ (8,219,220)
Basic weighted average common shares outstanding (in shares)	18,702,857	9,469,509	17,079,077	9,310,936
Potentially dilutive common shares (in shares)	1,592,692	0	0	0
Diluted weighted average common shares outstanding (in shares)	20,295,549	9,469,509	17,079,077	9,310,936
Basic weighted average earnings (loss) per common share (in dollars per share)	$ 0.18	$ (0.6)	$ (0.12)	$ (0.88)
Diluted weighted average earnings (loss) per common share (in dollars per share)	$ 0.17	$ (0.6)	$ (0.12)	$ (0.88)
Antidilutive securities (in shares)	0	273,607	1,032,369	292,959
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	0	273,607	156,327	292,959
Warrant [Member]
Antidilutive securities (in shares)	0	0	876,042	0

Note 8 - Accounts Receivable (D

Note 8 - Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jan. 01, 2022
Accounts Receivable, Credit Loss Expense (Reversal)	$ 12,000	$ 0	$ 12,000	$ 0
Accounts Receivable, after Allowance for Credit Loss	$ 7,802,121	$ 700,000	$ 7,802,121	$ 700,000	$ 383,786	$ 300,000

Note 8 - Accounts Receivable -

Note 8 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jan. 01, 2022
Gross accounts receivable – trade	$ 8,039,121	$ 383,786
Less: allowance for doubtful accounts	(237,000)	0
Accounts receivable – trade, net	$ 7,802,121	$ 383,786	$ 700,000	$ 300,000

Note 9 - Inventory - Summary of

Note 9 - Inventory - Summary of Inventory (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Finished goods	$ 5,026,734	$ 1,286,612
Less reserve for obsolete inventory	(40,000)	0
Total	$ 4,986,734	$ 1,286,612

Note 10 - VAT Receivable (Detai

Note 10 - VAT Receivable (Details Textual) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Value Added Tax Receivable, Current	$ 369,422	$ 432,769

Note 11 - Prepaid Expenses (Det

Note 11 - Prepaid Expenses (Details Textual) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expense, Current	$ 865,766	$ 45,679
Prepaid Expense, Noncurrent	$ 49,135	$ 49,078

Note 12 - Property and Equipm_3

Note 12 - Property and Equipment, Net (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Depreciation	$ 539,235	$ 329,272

Note 12 - Property and Equipm_4

Note 12 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Property and equipment gross	$ 6,451,424	$ 3,111,046
Less: accumulated depreciation	(2,404,570)	(1,865,244)
Property and equipment, net	4,046,854	1,245,802
Building [Member]
Property and equipment gross	2,116,000	0
Vehicles [Member]
Property and equipment gross	491,466	0
Furniture and Fixtures [Member]
Property and equipment gross	502,099	128,252
Land [Member]
Property and equipment gross	184,000	0
Leasehold Improvements [Member]
Property and equipment gross	123,630	47,792
Computer Equipment [Member]
Property and equipment gross	77,590	72,345
Rental Equipment [Member]
Property and equipment gross	57,759	37,531
Appliques [Member]
Property and equipment gross	2,160,096	2,160,096
Website Development [Member]
Property and equipment gross	$ 738,784	$ 665,030

Note 13 - Intangible Assets, _3

Note 13 - Intangible Assets, Net (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Amortization of Intangible Assets	$ 653,254	$ 18,750

Note 13 - Intangible Assets, _4

Note 13 - Intangible Assets, Net - Summary of Finite-lived Intangible Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets, Gross	$ 14,970,000	$ 250,000
Less: accumulated amortization	(853,252)	(199,999)
Total	14,116,748	50,001
Pharmacy Records [Member]
Finite-Lived Intangible Assets, Gross	8,100,000	0
Trade Names [Member]
Finite-Lived Intangible Assets, Gross	4,060,000	0
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets, Gross	2,560,000	0
Customer Contracts [Member]
Finite-Lived Intangible Assets, Gross	$ 250,000	$ 250,000

Note 13 - Intangible Assets, _5

Note 13 - Intangible Assets, Net - Future Amortization of Intangible Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
2023 (remaining three months)	$ 640,748
2024	2,563,000
2025	2,538,000
2026	2,538,000
2027	2,538,000
Thereafter	3,299,000
Total	$ 14,116,748	$ 50,001

Note 14 - Equity Method Inves_3

Note 14 - Equity Method Investment (Details Textual)	May 09, 2023 shares	May 05, 2023 USD ($) $ / shares shares	Dec. 29, 2022 shares	Sep. 30, 2023 USD ($) $ / shares shares	Jul. 01, 2023 shares	Dec. 31, 2022 $ / shares shares	Sep. 02, 2022 USD ($)	Aug. 30, 2022 USD ($) $ / shares shares
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001		$ 0.0001
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001		$ 0.0001
Common Stock, Shares Authorized (in shares) | shares				50,000,000		50,000,000
Long-Term Debt | $				$ 1,636,462
Progressive Care [Member]
Common Stock, Shares Authorized (in shares) | shares			100,000,000
Progressive Care [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			200
NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Original Debt, Amount | $		$ 2,900,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	570,599	570,599
NextPlat Corp [Member] | Debt Conversion Agreement [Member] | Progressive Care [Member]
Debt Instrument, Face Amount | $							$ 2,800,000
NextPlat Corp [Member] | Amendment [Member] | Progressive Care [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debt Instrument, Term (Year)		3 years
Maximum Secured Convertible Debentures Purchased According to Agreement | $		$ 10,000,000
Long-Term Debt | $				$ 0
Progressive Care [Member]
Investment Owned, Cost | $		$ 1,000,000						$ 8,300,000
Investment Owned, Balance, Shares (in shares) | shares		455,000			402,269			3,000
Investment Owned, Fair Value | $								$ 6,000,000
Unit, Number of Preferred Stock								1
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Investment Owned, Price Per Share (in dollars per share)		2.2
Progressive Care [Member] | Confidential Purchase And Release Agreement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)								$ 4
Progressive Care [Member] | NextPlat Corp [Member] | Debt Conversion Agreement [Member]
Debt Instrument, Face Amount | $								$ 2,800,000
Progressive Care [Member] | RXMD Warrants [Member]
Unit, Number of Warrants								1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 2,000
Progressive Care [Member] | PIPE Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Progressive Care [Member] | Conversion Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Progressive Care [Member] | Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)								0.001
Convertible Preferred Stock, Stated Value (in dollars per share)								$ 2,000
Preferred Stock, Votes Per Share								500
Preferred Stock, Convertible, Conversion Price (in dollars per share)								$ 4

Note 14 - Equity Method Inves_4

Note 14 - Equity Method Investment - Summary of Equity Method Investment (Details) - USD ($)		3 Months Ended		6 Months Ended	9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain		$ 6,138,051	$ 0		$ 6,138,051	$ 0
Equity in net loss of affiliate		(811,239)	$ 0		(811,239)	$ 0
Progressive Care [Member]
December 31, 2022, beginning balance				$ 5,260,525	5,260,525
Investment in Progressive Care Inc. and Subsidiaries					1,506,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain					6,138,051
Portion of loss from Progressive Care, Inc. and Subsidiaries				(1,603,649)	(1,603,649)
Depreciation expense due to cost basis difference (1)	[1]			(49,548)	(49,548)
Interest earned from convertible note receivable				21,443	21,443
Interest earned from amortization of premium on convertible note receivable				199,061	199,061
Elimination of intercompany interest earned				(6,944)	(6,944)
Change in accounting method as of July 1, 2023					(11,464,939)
September 30, 2023, carrying amount		$ 0			$ 0
Equity in net loss of affiliate				$ (1,439,637)
[1]NextPlat records depreciation expense on its estimated cost basis difference which is subject to change

Note 15 - Accounts Payable an_3

Note 15 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expense (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounts payable	$ 12,362,513	$ 1,194,067
Accrued wages and payroll liabilities	366,569	23,040
Accrued PBM fees	650,000	0
Rental deposits	0	4,325
Customer deposits payable	55,748	86,462
VAT liability & sales tax payable	6,480	5,685
U.K. income tax payable	0	23,771
Accrued legal fees	0	84,685
Pre-merger accrued other liabilities	0	88,448
Accrued interest	265	356
Accrued other liabilities	239,090	7,256
Total	$ 13,680,665	$ 1,518,095

Note 16 - Notes Payable (Detail

Note 16 - Notes Payable (Details Textual)		1 Months Ended			12 Months Ended
	Jul. 16, 2020 GBP (£)	Sep. 30, 2022 USD ($)	Jul. 31, 2022 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2023 USD ($)	Jul. 16, 2020 USD ($)	Jul. 16, 2020 GBP (£)
Long-Term Debt						$ 1,636,462
Collateralized Promissory Note [Member] | Progressive Care [Member]
Debt Instrument, Face Amount					$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Debt Instrument, Number of Payments					119
Debt Instrument, Periodic Payment					$ 11,901
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member]
Debt Instrument, Face Amount							$ 338,343	£ 250,000
Foreign Currency Exchange Rate, Translation							1.353372	1.353372
Debt Instrument, Interest Rate, Effective Percentage							0.10%	0.10%
Debt Instrument, Term (Year)	6 years
Debt Instrument, Periodic Payment, Principal | £	£ 4,166.67
Debt Instrument, Prepayment Limit, Percentage of Balance of Debenture							10%	10%
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4%
Note Obligation for Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount				$ 30,000
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Debt Instrument, Number of Payments				46
Debt Instrument, Periodic Payment				$ 331
Long-Term Debt						6,500
Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount			$ 90,000
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Debt Instrument, Number of Payments			60
Debt Instrument, Periodic Payment			$ 1,859
Long-Term Debt						78,000
Note Obligation for Vehicles [Member] | Progressive Care [Member]
Debt Instrument, Face Amount		$ 25,000
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Debt Instrument, Number of Payments		24
Debt Instrument, Periodic Payment		$ 1,143
Long-Term Debt						$ 13,000

Note 16 - Notes Payable - Sched

Note 16 - Notes Payable - Schedule of Debt (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Note payable	$ 1,636,462	$ 216,756
Less: current portion of notes payable	(385,303)	(60,490)
Long-term portion of notes payable	1,251,159	156,266
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,162,004	0
Note Payable Uncollateralized [Member]
Note payable	25,000	0
Note Payable Collateralized [Member]
Note payable	270,906	216,756
Insurance Premium Financing [Member]
Note payable	$ 178,552	$ 0

Note 16 - Notes Payable - Sch_2

Note 16 - Notes Payable - Schedule of Future Maturities (Details)	Sep. 30, 2023 USD ($)
2023 (remaining three months)	$ 144,420
2024	285,356
2025	175,435
2026	154,222
2027	123,597
Thereafter	753,432
Total	$ 1,636,462

Note 17 - Stockholders' Equity

Note 17 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Apr. 11, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Preferred Stock, Shares Authorized (in shares)		3,333,333		3,333,333
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Preferred Stock, Shares Outstanding (in shares)		0		0
Preferred Stock, Shares Issued (in shares)		0
Common Stock, Shares Authorized (in shares)		50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Common Stock, Shares, Issued (in shares)		18,724,596		14,402,025
Share-Based Payment Arrangement, Expense		$ 4,600	$ 2,000
Share-Based Payment Arrangement, Expense, Tax Benefit		$ 0	$ 0
Common Stock, Shares, Outstanding (in shares)		18,724,596		14,402,025
April 2023 Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)	3,428,571
Shares Issued, Price Per Share (in dollars per share)	$ 1.75
Proceeds from Issuance of Private Placement	$ 6,000

Note 18 - Related Party Trans_2

Note 18 - Related Party Transactions (Details Textual) - USD ($)						1 Months Ended		9 Months Ended		12 Months Ended
	Jul. 01, 2023	May 09, 2023	May 05, 2023	Feb. 01, 2023	Jul. 12, 2022	May 31, 2023	Apr. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 30, 2022
Common Stock, Par or Stated Value Per Share (in dollars per share)								$ 0.0001		$ 0.0001
Proceeds from Warrant Exercises								$ 689,750	$ 0
Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares)											105,000
Progressive Care [Member]
Investment Owned, Balance, Shares (in shares)	402,269		455,000								3,000
Investment Owned, Price Per Share (in dollars per share)			$ 2.2
Investment Owned, Cost			$ 1,000,000								$ 8,300,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001
Proceeds from Warrant Exercises	$ 506,000
Investment Owned, Balance, Shares From Warrants Exercised (in shares)	230,000
Debt Conversion Agreement [Member] | Predecessor Company [Member]
Long-Term Debt, Gross											$ 2,800,000
Progressive Care [Member]
Management and Administrative Service Revenue, Per Month				$ 25,000		$ 20,000
Proceeds From Management and Administrative Service								$ 175,000
Lauren Sturges Fernandez [Member]
Annual Salary					$ 95,000		$ 125,000
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold										$ 10,995
NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		570,599	570,599
NextPlat Corp [Member] | Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares)											45,653
Chief Executive Officer [Member] | Progressive Care [Member] | Inducement Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		190,000
Chief Executive Officer [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240
Chief Executive Officer [Member] | Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares)											18,261
Chief Executive Officer [Member] | Progressive Care [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares)	211,470
Board Member [Member] | Progressive Care [Member] | Inducement Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		30,000
Board Member [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240
Board Member [Member] | Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares)											18,261
Board Member [Member] | Progressive Care [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares)	130,571

Note 20 - Leases (Details Textu

Note 20 - Leases (Details Textual)		1 Months Ended				3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 02, 2021 USD ($) ft²	Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	May 31, 2018 USD ($)	Sep. 30, 2023 ft²	Sep. 30, 2023 USD ($) ft²	Sep. 30, 2023 GBP (£) ft²	Dec. 31, 2022 USD ($)
Operating Lease, Weighted Average Incremental Rate, Percent						3.75%			3.75%
Operating Lease, Impairment Loss							$ 0		$ 0
Office Space in Florida [Member]
Lessee, Operating Lease, Term of Contract (Month)	62 months
Area of Real Estate Property (Square Foot) | ft²	4,141
Annul Rent	$ 186,345
Annual Lease Increase, Percentage	3%
Facilities in Poole, England [Member]
Area of Real Estate Property (Square Foot) | ft²						2,660	2,660	2,660
Annul Rent							$ 37,107	£ 30,000
Foreign Currency Exchange Rate, Translation						1.24	1.24	1.24
Lessee, Operating Lease, Renewal Term (Month)						12 months	12 months	12 months
Progressive Care [Member] | Finance Obligation for Pharmacy Equipment [Member]
Finance Lease, Liability					$ 115,000
Finance Lease, Monthly Payment					$ 1,678
Lessee, Finance Lease, Term of Contract (Month)					84 months
Lessee, Finance Lease, Interest Rate					6%
Progressive Care [Member] | Computer Servers [Member]
Finance Lease, Liability			$ 51,000
Finance Lease, Monthly Payment			$ 1,411
Lessee, Finance Lease, Term of Contract (Month)			36 months
Progressive Care [Member] | Orlando Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)				66 months
Operating Lease, Monthly Payment				$ 4,310
Progressive Care [Member] | North Miami Beach Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)		60 months
Operating Lease, Monthly Payment		$ 5,237

Note 21 - Reportable Segments_2

Note 21 - Reportable Segments (Details Textual)	9 Months Ended
	Sep. 30, 2023
Number of Reportable Segments	2

Note 21 - Reportable Segments -

Note 21 - Reportable Segments - Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 15,290,171	$ 2,630,826	$ 21,123,687	$ 9,080,083
Cost of revenue	10,705,489	1,952,072	15,074,319	7,032,847
Selling, general and administrative	4,187,429	1,699,711	7,495,601	3,434,916
Salaries, wages and payroll taxes	2,483,432	651,219	4,039,307	1,957,592
Professional fees	520,726	356,306	1,385,474	839,509
Depreciation and amortization	871,066	136,457	1,200,825	348,022
Expenses, Including Cost of Revenue	18,768,142		29,195,526
Loss before other (income) expense	(3,477,971)	(2,164,939)	(8,071,839)	(4,532,803)
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	9,887,890	0	9,887,890	0
E-Commerce Revenue [Member]
Revenue	2,930,721		8,764,237
Pharmacy 340B Contract [Member]
Revenue	2,471,560	$ 0	2,471,560	$ 0
Consolidation, Eliminations [Member]
Revenue	0		0
Cost of revenue	0		0
Selling, general and administrative	(60,022)		(60,022)
Salaries, wages and payroll taxes	0		0
Professional fees	0		0
Depreciation and amortization	0		0
Expenses, Including Cost of Revenue	(60,022)		(60,022)
Loss before other (income) expense	60,022		60,022
Consolidation, Eliminations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0		0
Consolidation, Eliminations [Member] | E-Commerce Revenue [Member]
Revenue	0		0
Consolidation, Eliminations [Member] | Pharmacy 340B Contract [Member]
Revenue	0		0
E-Commerce [Member] | Operating Segments [Member]
Revenue	2,930,721		8,764,237
Cost of revenue	2,126,602		6,495,432
Selling, general and administrative	1,978,743		5,286,915
Salaries, wages and payroll taxes	563,915		2,119,790
Professional fees	277,872		1,142,620
Depreciation and amortization	163,512		493,271
Expenses, Including Cost of Revenue	5,110,644		15,538,028
Loss before other (income) expense	(2,179,923)		(6,773,791)
E-Commerce [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0		0
E-Commerce [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	2,930,721		8,764,237
E-Commerce [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	0		0
Healthcare Operations [Member] | Operating Segments [Member]
Revenue	12,359,450		12,359,450
Cost of revenue	8,578,887		8,578,887
Selling, general and administrative	2,268,708		2,268,708
Salaries, wages and payroll taxes	1,919,517		1,919,517
Professional fees	242,854		242,854
Depreciation and amortization	707,554		707,554
Expenses, Including Cost of Revenue	13,717,520		13,717,520
Loss before other (income) expense	(1,358,070)		(1,358,070)
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	9,887,890		9,887,890
Healthcare Operations [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	0		0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 2,471,560		$ 2,471,560

Note 21 - Reportable Segements

Note 21 - Reportable Segements - Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Total Assets	$ 66,195,187	$ 28,642,048
Operating Segments [Member] | E-Commerce [Member]
Total Assets	36,395,131
Operating Segments [Member] | Healthcare Operations [Member]
Total Assets	41,264,995
Consolidation, Eliminations [Member]
Total Assets	$ (11,464,939)

Note 22 - Concentrations (Detai

Note 22 - Concentrations (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Amazon [Member]
Concentration Risk, Percentage		53%	59.20%
Purchases [Member] | Supplier Concentration Risk [Member]
Number of Major Vendors	1
Purchases [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]
Concentration Risk, Percentage	99%

Note 22 - Concentrations - Sche

Note 22 - Concentrations - Schedules of Concentration of Risk (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 15,290,171	$ 2,630,826	$ 21,123,687	$ 9,080,083
Purchases [Member] | Supplier Concentration Risk [Member] | Globalstar Europe [Member]
Purchases	$ 186,000	$ 109,000	$ 706,000	$ 396,000
Percentage	9.70%	6.70%	10.60%	6.50%
Purchases [Member] | Supplier Concentration Risk [Member] | Iridium Satellite [Member]
Purchases			$ 798,000	$ 0
Percentage			12%	0%
Purchases [Member] | Supplier Concentration Risk [Member] | Garmin [Member]
Purchases	$ 444,000	$ 281,000	$ 1,494,000	$ 1,169,000
Percentage	23.20%	17.10%	22.50%	19.20%
Purchases [Member] | Supplier Concentration Risk [Member] | Network Innovations [Member]
Purchases	$ 188,000	$ 252,000	$ 809,000	$ 719,000
Percentage	9.90%	15.40%	12.20%	11.80%
Purchases [Member] | Supplier Concentration Risk [Member] | Satcom Global [Member]
Purchases	$ 226,000	$ 131,000
Percentage	11.80%	8%
Purchases [Member] | Supplier Concentration Risk [Member] | Cygnus Telecom [Member]
Purchases	$ 113,000	$ 181,000	$ 476,000	$ 1,213,000
Percentage	5.90%	11%	7.20%	19.90%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Percentage	100%	100%	100%	100%
Revenue	$ 2,930,721	$ 2,630,826	$ 8,764,237	$ 9,080,083
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Percentage	58.50%	74.30%	61.40%	77.30%
Revenue	$ 1,714,983	$ 1,954,967	$ 5,381,938	$ 7,019,811
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | North America [Member]
Percentage	25.20%	16.80%	25%	14.80%
Revenue	$ 737,189	$ 442,678	$ 2,194,309	$ 1,342,636
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | South America [Member]
Percentage	14.70%	0.40%	11.70%	0.40%
Revenue	$ 431,612	$ 10,273	$ 1,025,566	$ 32,578
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Asia Pacific [Member]
Percentage	0.80%	7.40%	1.40%	6.50%
Revenue	$ 23,943	$ 195,307	$ 120,836	$ 592,847
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Africa [Member]
Percentage	0.80%	1.10%	0.50%	1%
Revenue	$ 22,994	$ 27,601	$ 41,588	$ 92,211
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM A [Member]
Percentage	35%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM B [Member]
Percentage	31%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM C [Member]
Percentage	16%